Opinion statement
Multiple sclerosis is an autoimmune demyelinating disorder of the nervous system, in which almost all patients develop some degree of visual impairment during the disease. Optic neuritis is the most common and known visual affection and may be the initial clinical disease manifestation, but visual complaints can have a wide variety of presentations and some of them can lead to clinical confusion. Most symptoms are the result of acute injury and subsequent axonal loss in the afferent and efferent visual pathway, but others may be consequences of treatments. Currently, we can tell the functional and anatomical damage caused by multiple sclerosis by visual function test, measurement of eye movements, electrophysiological testing, optical coherence tomography, and magnetic resonance imaging. The purpose of this review is to describe the afferent and efferent visual symptoms associated with multiple sclerosis or multiple sclerosis treatment, and review the current and future therapeutic options available for them.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol. 2002;13(6):375–80.
Martínez-Lapiscina E, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe A, Torres-Torres R, et al. The visual pathway as a model to understand brain damage in multiple sclerosis. Mult Scler. 2014.
Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109(12):1673.
de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol. 2006;90(5):551.
Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77–83.
Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514.
Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804.
Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081.
Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576.
CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463.
Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242.
Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503.
Heron G, Thompson KJ, Dutton GN. The symptomatic Pulfrich phenomenon can be successfully managed with a coloured lens in front of the good eye—a long- term follow-up study. Eye (Lond). 2007;21:1469–72.
McGowan G, Ahmed TY, Heron G, Diaper C. The Pulfrich phenomenon; clumsiness and collisions which can be ameliorated. Pract Neurol. 2011;11(3):173–6.
Perkin GD, Rose FC. Uhthoff’s syndrome. Br J Ophthalmol. 1976;60(1):60–3.
Davis SL, Frohman TC, Crandall CG, et al. Modelling Uhthoff’s phenomenon in MS patients with internuclear ophthalmoparesis. Neurology. 2008;70(13 pt 2):1098Y1106.
Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. CONTINUUM Lifelong Learn Neurol. 2013;19(4):992–1006. The very latest and most comprehensive review of unusual symptoms and síndromes. in MS; essential reading.
Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1993;111:231–4.
Plant GT, Kermode AG, Turano G, et al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology. 1992;42:68–76.
Francis CE. Visual issues in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):687–702.
Zee DS. Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin Neurol. 1992;1:455–70.
Frohman EM, Frohman TC, O’Suilleabhain P, et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry. 2002;73:51–5.
Serra A, Derwenskus J, Downey DL, et al. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J Neurol. 2003;250:569–75.
Bolanos I, Lozano D, Cantu C. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol Scand. 2004;110:161–5.
Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4(2):111–21.
Niestroy A, Rucker JC, Leigh RJ. Neuro-ophthalmologic aspects of multiple sclerosis: using eye movements as a clinical and experimental tool. Clin Ophthalmol. 2007;I(3):267–72.
Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol. 2010;4:1409–22. A full update of the visual manifestations of multiple sclerosis and its management. Recommended reading.
Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818–25.
Starck M, Albrecht H, Pollman W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244:9–16.
Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol. 2005;7:69–77.
Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. J Neurol Neurosurg Psychiatry. 2003;74:1–4.
Buckley EG, Holgado S. Surgical treatment of upgaze palsy in Parinaud’s syndrome. J AAPOS. 2004;8:249–53.
Postert T, McMonagle U, Buttner T, et al. Paroxysmal convergence spasm in multiple sclerosis. Acta Neurol Scand. 1996;94(1):35–7.
Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10(3):505–12.
Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin. Clin Rev Allerg Immunol. 2005;29(3):173–84.
Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol. 1997;124(3):416–8.
Rubio JE, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina. 2003;23:546–8.
Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077–9.
Cohen JA, Rovaris M, Goodman AD, et al. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology. 2007;68(12):939–44.
Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290–7.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.
Highlights of prescribing information: Gilenya (fingolimod) capsules. Novartis. 2012.
Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–46.
Compliance with Ethics Guidelines
Conflict of Interest
Ruben Torres-Torres and Bernardo F. Sanchez-Dalmau declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Multiple Sclerosis and Related Disorders
Rights and permissions
About this article
Cite this article
Torres-Torres, R., Sanchez-Dalmau, B.F. Treatment of Acute Optic Neuritis and Vision Complaints in Multiple Sclerosis. Curr Treat Options Neurol 17, 328 (2015). https://doi.org/10.1007/s11940-014-0328-z
Published:
DOI: https://doi.org/10.1007/s11940-014-0328-z